BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Shree Ramkrishna Exports Group launches new venture Kriam Pharma

12 September 2025 | News

Kriam Pharma would supply its medicines even to South Africa



Shree Ramkrishna Exports (SRK) Family, a leader in the natural diamond industry, has taken a significant step into healthcare and holistic well-being with the launch of Kriam Pharma. The inauguration ceremony, held in Surat under the theme “Aarogyam: A New Flight towards Health & Healing”, marked the official unveiling of this new venture.

SRK Family seeks to carry forward its legacy of trust and responsibility to deliver quality healthcare through medicines that are accessible to all. For over six decades, SRK Group has been synonymous with transparency and integrity in the natural diamond sector, and Kriam Pharma aims to bring the same values into the world of medicine.

Kriam Pharma will focus on categories such as anti-diabetic, cardiac care, gastrointestinal, pain management, dermatology, vitamins and minerals and anti-infectives, covering both immediate and long-term healthcare needs. In a highly fragmented market, the company will deliver reliability, while adhering to the highest ethical standards.

Mayor Daksheshbhai Mavani congratulated SRK Family on the new venture and expressed hope that with support from the Bill & Melinda Gates Foundation, Kriam Pharma would supply its medicines even to South Africa. He said, “The company would initially focus on Gujarat and Maharashtra, adopting a direct-to-chemist distribution model for efficiency and trust.”

Kriam Pharma aims to supply medicines across every city, town and village in India by 2030, while creating more than 3,500 direct and indirect jobs. The company is also exploring exports to emerging markets with high demand for dependable and high-quality medicines.

Kriam Pharma is currently sourcing its products from leading Contract Development and Manufacturing Organisations (CDMOs) and plans to set up in-house manufacturing in the second phase.